– FRANCE, Paris – Abivax SA (EPA: ABVX / Nasdaq: ABVX), a biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced the appointment of Dr. Dominik Höchli (MD) to its Board of Directors, effective immediately, bringing over two decades of leadership experience in global biopharma, most notably a 20-year tenure at AbbVie/Abbott, where he served as VP of Global Marketing for Immunology and later as Head of Global Medical Affairs.
“We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical strategy and commercialization within immunology will be invaluable as we approach key clinical and regulatory inflection points for obefazimod,” said Board Chair, Sylvie Grégoire.
About Dr. Dominik Höchli
In addition to his experience at AbbVie, Dr. Dominik Höchli served as Interim CEO of Catapult Therapeutics, a hematology-oncology company, from 2021 to 2024. He is also the founder of Abinode, a pharmaceutical strategy consulting firm, and serves on the Board of Directors at Molecular Partners AG, where he is a member of both the Audit Committee and the Research & Development Committee.
Dr. Dominik Höchli said: “I’m excited to join the Board at a time when Abivax is entering a critical phase of clinical development and to support the company’s efforts to bring obefazimod to patients living with ulcerative colitis and Crohn’s disease.”
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
For more information: https://www.abivax.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.